View Older Stories View More Recent Stories

Dec 9, 2024 07:33AM Theratechnologies (THTX) Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
Dec 9, 2024 07:30AM Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
Dec 4, 2024 07:30AM Theratechnologies (THTX) Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
Dec 4, 2024 07:30AM Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
Dec 3, 2024 04:30PM Theratechnologies (THTX) Announces Resumed Production of EGRIFTA SV
Dec 3, 2024 04:30PM Theratechnologies Announces Resumed Production of EGRIFTA SV®
Dec 2, 2024 07:30AM Theratechnologies (THTX) Secures up to $75M in New Credit Facilities with TD Bank and Investissement Québec
Dec 2, 2024 07:30AM Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
Nov 26, 2024 07:32AM Theratechnologies (THTX) Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Nov 26, 2024 07:30AM Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Oct 17, 2024 02:00PM Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Oct 17, 2024 07:31AM Theratechnologies (THTX) Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab
Oct 17, 2024 07:30AM Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
Oct 10, 2024 07:30AM Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
Oct 9, 2024 07:30AM Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
Sep 26, 2024 07:30AM Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
Sep 17, 2024 05:01PM Theratechnologies (THTX) Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV in Early 2025
Sep 17, 2024 05:00PM Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
Sep 9, 2024 07:30AM Theratechnologies to Present at Upcoming Investor Conferences in September
Jul 10, 2024 07:30AM Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
Jun 26, 2024 07:30AM Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
May 23, 2024 05:00PM Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
May 9, 2024 04:30PM Theratechnologies Reports on its Annual Meeting of Shareholders
May 2, 2024 07:30AM Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Apr 15, 2024 04:15PM Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
Apr 8, 2024 04:30PM Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
Apr 5, 2024 11:01AM Theratechnologies (THTX) Appoints Elina Tea to its Board
Apr 5, 2024 11:00AM Theratechnologies Appoints Elina Tea to its Board of Directors
Apr 3, 2024 07:30AM Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
Mar 28, 2024 07:30AM Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
Mar 22, 2024 09:37AM Theratechnologies (THTX) Issues Update on Preclinical Oncology Research Program
Mar 22, 2024 09:36AM Theratechnologies Announces Update on its Preclinical Oncology Research Program
Mar 22, 2024 05:23AM Theratechnologies (THTX) Appoints Jordan Zwick to its Board
Mar 21, 2024 08:00PM Theratechnologies Appoints Jordan Zwick to its Board of Directors
Mar 21, 2024 07:31AM Theratechnologies (THTX) Initiates Increased Dose Level in Phase 1 Trial of Sudocetaxel Zendusortide
Mar 21, 2024 07:30AM Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Feb 29, 2024 04:34PM Theratechnologies (THTX) Announces Resignation of Alain Trudeau from Board
Feb 29, 2024 04:34PM Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
Feb 27, 2024 07:30AM Theratechnologies (THTX) Receives Refusal to File Letter for Trogarzo
Feb 27, 2024 07:30AM Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
Feb 21, 2024 07:30AM Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
Feb 20, 2024 07:32AM Theratechnologies (THTX) Reports Publication that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
Feb 20, 2024 07:30AM Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
Feb 15, 2024 07:30AM Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Feb 6, 2024 07:30AM Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Jan 24, 2024 07:05AM Theratechnologies (THTX) Receives CRL from the FDA for the F8 Formulation of Tesamorelin sBLA
Jan 24, 2024 07:00AM Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
Jan 23, 2024 07:33AM Theratechnologies (THTX) Receives Update from FDA on Tesamorelin F8 Supplemental BLA
Jan 23, 2024 07:30AM Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
Jan 2, 2024 07:30AM Theratechnologies (THTX) Submits sBLA for Trogarzo Intramuscular Method of Administration to FDA
View More Recent Stories View Older Stories